Skip to main content
. 2023 Jun 20. Online ahead of print. doi: 10.1016/j.vaccine.2023.06.053

Fig. 2.

Fig. 2

Tumor burden-impaired SARS-CoV-2 RBD-specific B cell responses are rebounded upon PD-1/PD-L1 ICB therapy. A. Flow cytometry analysis of lymphocytes in vaccine-dLNs. The numbers adjacent to the outlined areas indicate the percentages of CD19+B220+ B cells. B, C. Frequency (B) and number (C) of B cells in vaccine-dLNs. D. Flow cytometry analysis of CD19+B220+ B cells in vaccine-dLNs. The numbers adjacent to the outlined areas indicate the percentages of SARS-CoV-2 prototype RBD-specific B cells. E, F. Frequency (E) and number (F) of SARS-CoV-2 prototype RBD-specific B cells in vaccine-dLNs. G. Flow cytometry analysis of CD19+B220+ B cells in vaccine-dLNs. The numbers adjacent to the outlined areas indicate the percentages of SARS-CoV-2 Omicron RBD-specific B cells. H, I. Frequency (H) and number (I) of SARS-CoV-2 Omicron RBD-specific B cells in vaccine-dLNs. J. Flow cytometry analysis of CD19+B220+ B cells in vaccine-dLNs. The numbers adjacent to the outlined areas indicate the percentages of FAS+PNA+ GC B cells. K, L. Frequency (K) and number (L) of FAS+PNA+ GC B cells in vaccine-dLNs. ns, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001. The data are representative of two independent experiments with five mice per group. Error bars (B, C, E, F, H, I, K, L) indicate s.e.m..